Market access workshops, roundtables and payer advisory boards provide vital input and cross-functional alignment on scenario planning, pricing, access and evidence strategies for pharma and medical technology companies. In this blog post we discuss how well-facilitated virtual workshops can meet the same strategic objectives of face-to-face meetings. We got into the business of offering virtual […]
2018 has been an exciting year for Valid Insight. One of our proudest achievements was the launch of two new innovations, our Pricing and Market Access Simulator app, and TRAVELLESS™️, our virtual advisory board solution. The Pricing and Market Access Simulator app has been three years in development and is a unique product that allows […]
In order to support effective decision making and deliver sustained returns in a complex, dynamic healthcare environment, pharmaceutical, biotech and medical device companies need an expert-led market access strategy that considers the changing nature of the real-life marketplace. These strategies should not only focus on achieving the commercial objectives for a product but also enable […]
Approximately 30 million people live with rare diseases in Europe. In a drive to improve treatment for people with these complex conditions, a cross border cooperation via Directive 2011/24/EU “Patient’s rights in cross border healthcare,”1 has provided a framework for the development of European Reference Networks (ERNs).
The Republic of Ireland has become the first country in Europe to switch a whole population suffering from Haemophilia A and Haemophilia B from short-acting clotting factors to new generation, extended half-life (EHL) therapies. This news highlights the importance of a good tendering strategy to ensure market access.
With rising treatment prices and healthcare spending, payer organisations are making efforts to contain costs, with the unintended consequence of putting up treatment access barriers. Hence, there is a growing interest in more innovative agreements, such as performance-based (reimbursements tied to conditions around producing outcomes or bridging evidence gaps), finance-based (rebates/discounts for excesses in agreed-upon […]
2017 saw the National Institute for Health and Care Excellence (NICE) board, with input from the NHS England Specialised Services Commissioning Committee, agree to a change that will have a substantial impact on both patients and the companies bringing ultra-orphan drugs to market. In this article we consider what is going to change and how […]